Scientists have made a groundbreaking achievement in the fight against colorectal cancer. The advanced drug Dostarlimab has completely cured colorectal cancer in all trial participants, marking a historic milestone in cancer treatment. The U.S. Food and Drug Administration (FDA) has awarded Dostarlimab the prestigious "Breakthrough Therapy" status, which will expedite its development and approval for the market. This status is given to drugs showing significant promise in treating serious diseases. In clinical trials at Memorial Sloan Kettering Cancer Center, Dostarlimab eradicated tumors in all participants. The initial report covered 24 patients, later updated to 42. Every patient remains cancer-free, with no signs of recurrence for up to four years in some cases.